ClinicalTrials.gov
ClinicalTrials.gov Menu

The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00095654
Recruitment Status : Completed
First Posted : November 8, 2004
Last Update Posted : November 10, 2009
Sponsor:
Collaborators:
Canadian Institutes of Health Research (CIHR)
Aventis Pharmaceuticals
GlaxoSmithKline
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
Gerstein, Hertzel, MD

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Actual Study Completion Date : October 2006
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):